NRSN

NeuroSense Therapeutics Ltd.

News

prnewswire.comNeuroSense Granted South Korean Patent Covering PrimeC Composition for ALSprnewswire.comJun 11

prnewswire.comNeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Compositionprnewswire.comJun 9

prnewswire.comNeuroSense Announces Pricing of Insider-Led PIPE Financingprnewswire.comApr 28

defenseworld.netBrokerages Set NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Price Target at $8.50defenseworld.netApr 7

prnewswire.comNeuroSense Granted Brazilian Patent Covering PrimeC Compositionprnewswire.comApr 6

Trade NRSN

About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS). Additionally, its early-stage research pipeline features StabiliC, a potential treatment for Parkinson's disease, and CogniC, which is under development for Alzheimer's disease. Established in 2017, NeuroSense Therapeutics Ltd. is headquartered in Herzliya, Israel.

CEO: Alon Ben-Noon
IPO Date: Dec 9, 2021

Market Data

Open: $0.75
High: $0.8046
Low: $0.74
Volume: 228.7K
Avg Volume: 139.9K
52W High: $2.52
52W Low: $0.63

Valuation

Market Cap: $20M
Enterprise Value: $20M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-7.7M
Revenue: $0
Net Income: $-11M
Cash: $166k
Debt: $170k

Events

EarningsJun 30

EPS est. -0.195